Search Results - "Church, Amy K."

Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia by Baig, Nisar A, Taylor, Ronald P, Lindorfer, Margaret A, Church, Amy K, LaPlant, Betsy R, Pettinger, Adam M, Shanafelt, Tait D, Nowakowski, Grzegorz S, Zent, Clive S

“…Ofatumumab (OFA), a human CD20-targeting mAb, kills B lymphocytes using the innate immune system including complement-dependent cytotoxicity (CDC). The…”
Get full text

BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma by Correia, Cristina, Schneider, Paula A., Dai, Haiming, Dogan, Ahmet, Maurer, Matthew J., Church, Amy K., Novak, Anne J., Feldman, Andrew L., Wu, Xiaosheng, Ding, Husheng, Meng, X. Wei, Cerhan, James R., Slager, Susan L., Macon, William R., Habermann, Thomas M., Karp, Judith E., Gore, Steven D., Kay, Neil E., Jelinek, Diane F., Witzig, Thomas E., Nowakowski, Grzegorz S., Kaufmann, Scott H.

“…Follicular lymphoma (FL), an indolent neoplasm caused by a t(14;18) chromosomal translocation that juxtaposes the BCL2 gene and immunoglobulin locus, has a…”
Get full text

Bone marrow stromal cells protect lymphoma B‐cells from rituximab‐induced apoptosis and targeting integrin α‐4‐β‐1 (VLA‐4) with natalizumab can overcome this resistance by Mraz, Marek, Zent, Clive S., Church, Amy K., Jelinek, Diane F., Wu, Xiaosheng, Pospisilova, Sarka, Ansell, Stephen M., Novak, Anne J., Kay, Neil E., Witzig, Thomas E., Nowakowski, Grzegorz S.

“…Summary Rituximab improves the outcome of patients with non‐Hodgkin lymphoma, but does not completely eradicate residual B‐cell populations in the…”
Get full text

Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement by Baig, Nisar A., Taylor, Ronald P., Lindorfer, Margaret A., Church, Amy K., Laplant, Betsy R., Pavey, Emily S., Nowakowski, Grzegorz S., Zent, Clive S.

“…Abstract Complement dependent cytotoxicity (CDC) is an important mechanism of action for monoclonal antibodies (mAbs) used in the treatment of chronic…”
Get full text

5.15 Resistance to Complement-Dependent Cytotoxicity in Chronic Lymphocytic Leukemia Cells from Patients Treated with Ofatumumab by Baig, Nisar A, Taylor, Ronald P, Lindorfer, Margaret A, Church, Amy K, LaPlant, Betsy R, Pavey, Emily S, Shanafelt, Tait D, Call, Timothy G, Kay, Neil E, Nowakowski, Grzegorz S, Zent, Clive S

Get full text

Complement Activation and Cytotoxicity In CLL Cells Treated with Alemtuzumab and Ofatumumab: Evidence for Multiple Mechanisms of Resistance to Complement Dependent Cytotoxicity by Baig, Nisar A, Church, Amy K, Nowakowski, Grzegorz S., Taylor, Ronald P, Lindorfer, Margaret A, Zent, Clive S.

“…Abstract 3575 Unconjugated monoclonal antibodies (MoAb) have proven value in the therapy of CLL, and alemtuzumab (ALEM) has efficacy in patients with purine…”
Get full text

Resistance to Complement Dependent Cytotoxicity in CLL Cells From Patients Treated with Ofatumumab by Baig, Nisar A., Taylor, Ronald P., Lindorfer, Margaret A., Church, Amy K, LaPlant, Betsy R., Pavey, Emily S., Shanafelt, Tait D., Call, Timothy G., Kay, Neil, Nowakowski, Grzegorz S., Zent, Clive S.

“…Abstract 2836 Monoclonal antibodies (mAb) are an effective but non-curative treatment of CLL. Although the mechanisms of action of mAb in vivo are not fully…”
Get full text

Complement dependent cytotoxicity (CDC) in chronic lymphocytic leukemia (CLL): Ofatumumab enhances alemtuzumab CDC and reveals cells resistant to activated complement by Baig, Nisar A., Taylor, Ronald P., Lindorfer, Margaret A., Church, Amy K., LaPlant, Betsy R., Pavey, Emily S., Nowakowski, Grzegorz S., Zent, Clive S.

“…Complement dependent cytotoxicity (CDC) is an important mechanism of action for monoclonal antibodies (mAb) used in the treatment of chronic lymphocytic…”
Get full text

Bone Marrow Stromal Cells Protect Lymphoma B-cells from Rituximab-Induced Apoptosis and Targeting Integrin alfa-4-beta-1 (VLA-4) with Natalizumab can Overcome this Resistance by Mraz, Marek, Zent, Clive S., Church, Amy K., Jelinek, Diane F., Wu, Xiaosheng, Pospisilova, Sarka, Ansell, Stephen M., Novak, Anne J., Kay, Neil E., Witzig, Thomas E., Nowakowski, Grzegorz S.

“…Rituximab improves the outcome of patients with non-Hodgkin lymphoma, but does not completely eradicate residual B-cell populations in the microenvironment of…”
Get full text

Interactions with the Microenvironment Protect Lymphoma B-Cells From Rituximab Induced Apoptosis and Could Represent a Therapeutic Target by Mraz, Marek, Zent, Clive S., Church, Amy K, Baig, Nisar A, Jelinek, Diane F., Wu, Xiaosheng, Pospisilova, Sarka, Ansell, Stephen M., Novak, Anne J., Witzig, Thomas E., Nowakowski, Grzegorz S.

“…Abstract 3115 Rituximab significantly improves the outcome of patients with B-cell non-Hodgkin lymphomas, but it does not completely eradicate residual B-cell…”
Get full text